Literature DB >> 32295784

Dual Relief of T-lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial Malignancies.

Camille-Charlotte Balança1, Clara-Maria Scarlata1, Marie Michelas1, Christel Devaud1, Victor Sarradin1,2, Camille Franchet3,4, Carlos Martinez Gomez1,5, Carlos Gomez-Roca1,2, Marie Tosolini6, Diana Heaugwane7, Françoise Lauzéral-Vizcaino1,4, Lucile Mir-Mesnier8, Virginie Féliu1, Carine Valle6, Frédéric Pont6, Gwénaël Ferron5, Laurence Gladieff2, Stéphanie Motton9, Yann Tanguy Le Gac9, Agnès Dupret-Bories5, Jérôme Sarini5, Benjamin Vairel9, Claire Illac7, Aurore Siegfried-Vergnon3, Eliane Mery7, Jean-Jacques Fournié1, Sébastien Vergez4,9, Jean-Pierre Delord1,2,4, Philippe Rochaix7, Alejandra Martinez1,5, Maha Ayyoub10,4,8.   

Abstract

Although understanding of T-cell exhaustion is widely based on mouse models, its analysis in patients with cancer could provide clues indicating tumor sensitivity to immune checkpoint blockade (ICB). Data suggest a role for costimulatory pathways, particularly CD28, in exhausted T-cell responsiveness to PD-1/PD-L1 blockade. Here, we used single-cell transcriptomic, phenotypic, and functional approaches to dissect the relation between CD8+ T-cell exhaustion, CD28 costimulation, and tumor specificity in head and neck, cervical, and ovarian cancers. We found that memory tumor-specific CD8+ T cells, but not bystander cells, sequentially express immune checkpoints once they infiltrate tumors, leading, in situ, to a functionally exhausted population. Exhausted T cells were nonetheless endowed with effector and tumor residency potential but exhibited loss of the costimulatory receptor CD28 in comparison with their circulating memory counterparts. Accordingly, PD-1 inhibition improved proliferation of circulating tumor-specific CD8+ T cells and reversed functional exhaustion of specific T cells at tumor sites. In agreement with their tumor specificity, high infiltration of tumors by exhausted cells was predictive of response to therapy and survival in ICB-treated patients with head and neck cancer. Our results showed that PD-1 blockade-mediated proliferation/reinvigoration of circulating memory T cells and local reversion of exhaustion occur concurrently to control tumors. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32295784     DOI: 10.1158/2326-6066.CIR-19-0855

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  10 in total

Review 1.  Single-Cell Techniques and Deep Learning in Predicting Drug Response.

Authors:  Zhenyu Wu; Patrick J Lawrence; Anjun Ma; Jian Zhu; Dong Xu; Qin Ma
Journal:  Trends Pharmacol Sci       Date:  2020-11-02       Impact factor: 14.819

2.  Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study.

Authors:  Victor Sarradin; Amélie Lusque; Thomas Filleron; Florence Dalenc; Camille Franchet
Journal:  Breast Cancer Res       Date:  2021-05-26       Impact factor: 6.466

Review 3.  The regulatory function of mixed lineage kinase 3 in tumor and host immunity.

Authors:  Sandeep Kumar; Sunil Kumar Singh; Basabi Rana; Ajay Rana
Journal:  Pharmacol Ther       Date:  2020-10-09       Impact factor: 13.400

Review 4.  Gutting it Out: Developing Effective Immunotherapies for Patients With Colorectal Cancer.

Authors:  Carolina Mendonça Gorgulho; Anuradha Krishnamurthy; Anastasia Lanzi; Jérôme Galon; Franck Housseau; Ramon Kaneno; Michael T Lotze
Journal:  J Immunother       Date:  2021 Feb-Mar 01       Impact factor: 4.912

5.  PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells.

Authors:  Camille-Charlotte Balança; Anna Salvioni; Clara-Maria Scarlata; Marie Michelas; Carlos Martinez-Gomez; Carlos Gomez-Roca; Victor Sarradin; Marie Tosolini; Carine Valle; Frédéric Pont; Gwénaël Ferron; Laurence Gladieff; Sébastien Vergez; Agnès Dupret-Bories; Eliane Mery; Philippe Rochaix; Jean-Jacques Fournié; Jean-Pierre Delord; Christel Devaud; Alejandra Martinez; Maha Ayyoub
Journal:  JCI Insight       Date:  2021-01-25

6.  Single-Cell RNAseq Profiling of Human γδ T Lymphocytes in Virus-Related Cancers and COVID-19 Disease.

Authors:  Juan Pablo Cerapio; Marion Perrier; Fréderic Pont; Marie Tosolini; Camille Laurent; Stéphane Bertani; Jean-Jacques Fournie
Journal:  Viruses       Date:  2021-11-03       Impact factor: 5.048

7.  Circulating Exhausted PD-1+CD39+ Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis Blockade.

Authors:  Carlos Martinez-Gomez; Marie Michelas; Clara-Maria Scarlata; Anna Salvioni; Carlos Gomez-Roca; Victor Sarradin; Françoise Lauzéral-Vizcaino; Virginie Féliu; Agnès Dupret-Bories; Gwénaël Ferron; Jérôme Sarini; Christel Devaud; Jean-Pierre Delord; Camille-Charlotte Balança; Alejandra Martinez; Maha Ayyoub
Journal:  Cancers (Basel)       Date:  2022-07-28       Impact factor: 6.575

8.  PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung.

Authors:  Patrick Micke; Carina Strell; Torsten Goldmann; Sebastian Marwitz; Dörte Nitschkowski; Rosemarie Krupar; Max Backman; Hedvig Elfving; Viktoria Thurfjell; Amanda Lindberg; Hans Brunnström; Linnea La Fleur; Artur Mezheyeuski; Johanna Sofia Margareta Mattsson; Johan Botling
Journal:  Cancer Immunol Immunother       Date:  2021-02-12       Impact factor: 6.968

Review 9.  Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer.

Authors:  Ching-Hung Hsieh; Cheng-Zhe Jian; Liang-In Lin; Guan-Sian Low; Ping-Yun Ou; Chiun Hsu; Da-Liang Ou
Journal:  Cancers (Basel)       Date:  2022-01-07       Impact factor: 6.639

10.  Phased differentiation of γδ T and T CD8 tumor-infiltrating lymphocytes revealed by single-cell transcriptomics of human cancers.

Authors:  Juan-Pablo Cerapio; Marion Perrier; Camille-Charlotte Balança; Pauline Gravelle; Fréderic Pont; Christel Devaud; Don-Marc Franchini; Virginie Féliu; Marie Tosolini; Carine Valle; Fréderic Lopez; Anne Quillet-Mary; Loic Ysebaert; Alejandra Martinez; Jean Pierre Delord; Maha Ayyoub; Camille Laurent; Jean-Jacques Fournie
Journal:  Oncoimmunology       Date:  2021-09-18       Impact factor: 8.110

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.